Background Podocyte has inflammatory role in the development of diabetic nephropathy （DN）. Mycophenolate mofetil （MMF）, an anti-inflammatory agent, can suppress macrophage infiltration and reduce renal injury in s...Background Podocyte has inflammatory role in the development of diabetic nephropathy （DN）. Mycophenolate mofetil （MMF）, an anti-inflammatory agent, can suppress macrophage infiltration and reduce renal injury in streptozotocin-induced diabetic rats. Angiotensin II receptor blocker （ARB）, another renal protecting agent, can decrease podocyte loss in DN. In this study, we detected the expression levels of monocyte chemoattractant protein-1 （MCP-1） and nephrin to evaluate podocyte＇s role in inflammatory reaction in DN, observe and compare the effect of MMF alone and in combination with valsartan, on preventing podocyte loss in streptozotocin （STZ） induced diabetic rats. Methods Diabetic model was constructed in uninephrectomized male Wistar rats by single peritoneal injection of STZ （65 mg/kg）. The successfully induced diabetic rats were randomly divided into four groups： diabetes without treatment group （DM）, valsartan treated group （DMV）, MMF treated group （DMM）, and combined therapy group （DMVM）. Normal rats of the same sibling were chosen as control （NC）. At the end of the 8th week, serum biochemistry, 24-hour urinary protein （LIP） and the ratio of kidney weight/body weight （RWK/B） were measured. The rats were sacrificed for the observation of renal histomorphology through light and electron microscope. Nephrin, desmin and MCP-1 levels were detected by semi-quantitative immunohistochemical assays. Real-time quantitative PCR was used to detect the mRNA levels of nephrin and MCP-1. Results Compared with group NC, serum glucose level, 24-hour LIP and RWK/B in group DM were significantly higher （P〈0.01）, and the nephrin mRNA level in DM group was significantly lower （P〈0.05）. The nephrin mRNA expression levels in group DMV, DMM and DMVM were all higher than that of DM group （P〈0.05） and no significant differences were found among the three treatment groups （P〉0.05）. Treatment with MMF, valsartan or their combination could significantly d展开更多
基金the National Natural Science Foundation of China (No. 30570866).
文摘Background Podocyte has inflammatory role in the development of diabetic nephropathy （DN）. Mycophenolate mofetil （MMF）, an anti-inflammatory agent, can suppress macrophage infiltration and reduce renal injury in streptozotocin-induced diabetic rats. Angiotensin II receptor blocker （ARB）, another renal protecting agent, can decrease podocyte loss in DN. In this study, we detected the expression levels of monocyte chemoattractant protein-1 （MCP-1） and nephrin to evaluate podocyte＇s role in inflammatory reaction in DN, observe and compare the effect of MMF alone and in combination with valsartan, on preventing podocyte loss in streptozotocin （STZ） induced diabetic rats. Methods Diabetic model was constructed in uninephrectomized male Wistar rats by single peritoneal injection of STZ （65 mg/kg）. The successfully induced diabetic rats were randomly divided into four groups： diabetes without treatment group （DM）, valsartan treated group （DMV）, MMF treated group （DMM）, and combined therapy group （DMVM）. Normal rats of the same sibling were chosen as control （NC）. At the end of the 8th week, serum biochemistry, 24-hour urinary protein （LIP） and the ratio of kidney weight/body weight （RWK/B） were measured. The rats were sacrificed for the observation of renal histomorphology through light and electron microscope. Nephrin, desmin and MCP-1 levels were detected by semi-quantitative immunohistochemical assays. Real-time quantitative PCR was used to detect the mRNA levels of nephrin and MCP-1. Results Compared with group NC, serum glucose level, 24-hour LIP and RWK/B in group DM were significantly higher （P〈0.01）, and the nephrin mRNA level in DM group was significantly lower （P〈0.05）. The nephrin mRNA expression levels in group DMV, DMM and DMVM were all higher than that of DM group （P〈0.05） and no significant differences were found among the three treatment groups （P〉0.05）. Treatment with MMF, valsartan or their combination could significantly d
